Information Center

VIOXX® (rofecoxib) Information Center

The information set forth in the documents posted on this page was factually accurate on the date it was issued. While this information remains on Merck's Web site, the company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of this information should not rely on it as current or accurate after the issuance dates.

LITIGATION INFORMATION
29 Jun 2010 Merck Wins Case Filed by Louisiana Attorney General Involving VIOXX®
27 Apr 2010 U.S. Supreme Court Affirms Lower Court Decision on Merck Federal Securities Class Action
12 Apr 2010 Statement on Vioxx® Consumer Product Trial in U.S. District Court for the Eastern District of Louisiana.

* More


Scientific Information
25 July 2007 Statement Regarding the Publications of Two VIOXX® Studies: The ViP Trial in Current Medical Research and Opinion and The VICTOR Trial in the New England Journal of Medicine (Adobe Acrobat File PDF* 22KB)
03 July 2007 VIOXX® Update: Statement on VICTOR Study (Adobe Acrobat File PDF* 22KB)
12 Sep 2006 Merck Statement about COX-2 Inhibitor Review Studies in the Journal of the American Medical Association (Adobe Acrobat File PDF* 23KB)

* More


COMPANY STATEMENTS
30 April 2009 Merck Responds to Questions about the Australasian Journal of Bone and Joint Medicine Journal (Adobe Acrobat File PDF* 18KB)
06 Sep 2006 Report of The Honorable John S. Martin, Jr. to the Special Committee of the Board of Directors of Merck & Co., Inc. Concerning the Conduct of Senior Management in the Development and Marketing of VIOXX®
06 Sep 2006 Statement on the Martin Report by William G. Bowen (Adobe Acrobat File PDF* 8KB)
VIOXX® (rofecoxib) Information Center

Official Merck site presents details of research, court cases, and US Department of Justice Investigations.
www.merck.com